The ruling would be viewed as a negative development for Lupin and Zydus, as it effectively blocks their ability to market the generic drug in the US. Analysts suggest the companies may also face financial penalties.
The ruling would be viewed as a negative development for Lupin and Zydus, as it effectively blocks their ability to market the generic drug in the US. Analysts suggest the companies may also face financial penalties.